– The vaccine appears to be effective against cervical cancer
A study published in The Lancet appears to be demonstrating the effectiveness of the vaccine against papillomavirus infection, which causes cervical cancer.
Cases of cervical cancer of the uterus have declined, especially among British women who have been vaccinated against papillomavirus infection, the cause of these cancers, a study published on Thursday found.
“Our study provides the first direct evidence of the effectiveness of the vaccine against human papillomavirus (HPV) by bivalent vaccine cervix on the frequency of cervical cancer”, summarize the authors of this report. Work published in “The Lancet”. Cervical cancers are almost always caused by a sexually transmitted infection with papillomavirus.
Vaccines against it have been available since the mid-2000s. So many countries have launched a campaign among adolescents who have the idea of getting vaccinated before being sexually active. Although the coverage rate was much lower than the targets, in the case of France it also extended to boys this year.
Read with limitations
To date, the effectiveness of vaccines against infection and the development of pre-cancerous lesions is well known. But the data on the frequency of reported cancers are less accurate. This is a contribution to the “Lancet” study. According to its research, there has been a significant reduction in cases of cervical cancer among women eligible for the UK vaccine campaign launched in the late 2000s.
This decrease is measured in relation to the proportion of cases in previous generations, especially observed in pre-vaccinated women aged 12 or 13 years. In recent years, cervical cancer has almost disappeared.
These conclusions have limitations. Even without the vaccine, researchers have only diagnosed a limited number of cancers at this age, which does not exceed 25 years today. They therefore stressed the need to continue to study the frequency of cancers in the coming years.
In addition, to maintain long-term adaptation, the study saw only women who had benefited from British rural areas in its early stages. However, at that time the Cervix vaccine produced by the GSK laboratory was used. Since then, it has been replaced by Gordasil from American Merck, MSD says outside the United States, the study of which has given no conclusions.